Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 rusfertide add-on study in adults with polycythemia vera
MOH_2022-07-04_011889Phase 3Recruiting
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Jun 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polycythemia vera (PV) comparing Rusfertide add-on with Placebo add-on (2 arms). Primary endpoint: Hematocrit control. Started Jun 2022; status: recruiting.
02
Drugs
rusfertide
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on MOH_2022-07-04_011889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-04_011889.